NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

中國的Dasatinib市場的相關調查報告書(2021年∼2025年)

Investigation Report on China's Dasatinib Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1008260
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Dasatinib市場的相關調查報告書(2021年∼2025年) Investigation Report on China's Dasatinib Market 2021-2025
出版日期: 2021年05月28日內容資訊: 英文 50 Pages
簡介

在中國市場的Dasatinib的銷售量從2016年到2020年年年增加著,2018年達成最大的成長。從2017年的5,100萬人民幣到2018年7,500萬人民幣,年間成長率成為48.72%。增加的主要理由,是中國進行醫療費削減的配合措施,2017年全國藥價談判以後,規定費用的70%由保險承擔。從2016年到2020年之間Dasatinib的銷售額以28.55%的年複合成長率成長著。

中國的Dasatinib市場擴大,分析從2021年到2025年銷售額有增加趨勢。中國的適應症的批准數量增加,有銷售額增加的可能性。

本報告提供中國的Dasatinib市場的相關調查,市場規模和預測,趨勢,COVID-19的影響,價格,成長要素和機會,威脅,課題,市場佔有率等資訊。

目錄

第1章 Dasatinib的相關概念

  • Dasatinib的適應症
  • 中國的Dasatinib的開發
  • 中國的Dasatinib的政府核准
  • COVID-19對中國的Dasatinib銷售的影響

第2章 中國的Dasatinib銷售(2016-2020)

  • Dasatinib的銷售量
    • 總銷售額
    • 各地區的銷售量
  • Dasatinib的銷售量
    • 整體銷售量
    • 各地區銷售量
  • 中國的各劑型Dasatinib銷售(2016-2020)
    • 錠劑
    • 其他的劑型分析

第3章 中國的主要Dasatinib製造商分析(2016-2020)

  • 主要的Dasatinib製造商市場佔有率分析
    • 各銷售額市場佔有率調查
    • 各銷售量市場佔有率調查
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    • 企業簡介
    • Yinishu(Chia Tai Tianqing Pharmaceutical Group Co., Ltd.的Dasatinib)在中國的銷售
  • Bristol-Myers Squibb Pharma EEIG
    • 企業簡介
    • SPRYCEL(Bristol-Myers Squibb Pharma EEIG的Dasatinib)在中國的銷售

第4章 中國的各種製造商的Dasatinib的價格(2020-2021)

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.(Yinish)
  • Bristol-Myers Squibb Pharma EEIG(SPRYCEL)

第5章 中國的Dasatinib市場預測(2021-2025)

  • 中國的Dasatinib市場開發的有影響力的要素
    • COVID-19對中國的Dasatinib市場的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2105495

Dasatinib, developed by Bristol-Myers Squibb, is an anti-tumor drug. It was first approved by the FDA in 2006 for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic and accelerated phases that are resistant or intolerant to previous treatment with imatinib. In 2011, Dasatinib was approved in China. By 2020, the two manufacturers in China's Dasatinib market are Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Bristol-Myers Squibb Pharma EEIG.

According to CRI's market research, the sales of Dasatinib have increased year by year from 2016 to 2020, with the most significant growth in 2018. The annual growth rate is 48.72 % from CNY51 million in 2017 to CNY75 million in 2018. The main reason for the increase is that China has undertaken an effort to cut healthcare costs, requiring insurance to cover 70% of costs since the national drug price negotiations in 2017. The CAGR of Dasatinib sales in 2016-2020 is 28.55%.

CRI analyzes that its sales will have an upward trend from 2021 to 2025 as the Chinese Dasatinib market expands. At present, 3 companies in China are in the approval stage of Dasatinib generic drugs. After the success of the approvals, the competition in the Chinese Dasatinib market will become more intense and the price will be less than before. Hence, the sales volume will increase accordingly. In addition, Dasatinib has been approved for 4 indications internationally, and only 2 indications have been approved in China. The number of indications approved in China is likely to increase, then sales still have the potential to increase.

Topics Covered:

  • The impact of COVID-19 on China's Dasatinib market
  • Sales value of China's Dasatinib 2016-2020
  • Competitive landscape of China's Dasatinib market
  • Prices of Dasatinib in China
  • Prices of Dasatinib in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Dasatinib market
  • Prospect of China's Dasatinib market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Dasatinib

  • 1.1 Indications for Dasatinib
  • 1.2 Development of Dasatinib in China
  • 1.3 Governmental Approval of Dasatinib in China
  • 1.4 The Impact of COVID-19 on Dasatinib sales in China

2 Sales of Dasatinib in China, 2016-2020

  • 2.1 Sales Value of Dasatinib
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Regions
  • 2.2 Sales Volume of Dasatinib
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Regions
  • 2.3 Sales of Dasatinib by Dosage Form in China, 2016-2020
    • 2.3.1 Tablet
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Dasatinib Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Dasatinib Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales Volume
  • 3.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Yinishu (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Dasatinib) in China
  • 3.3 Bristol-Myers Squibb Pharma EEIG
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of SPRYCEL (Bristol-Myers Squibb Pharma EEIG's Dasatinib) in China

4 Prices of Dasatinib for Different Manufacturers in China, 2020-2021

  • 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Yinish)
  • 4.2 Bristol-Myers Squibb Pharma EEIG (SPRYCEL)

5 Prospect of Chinese Dasatinib Market, 2021-2025

  • 5.1 Influential Factors of Chinese Dasatinib Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Dasatinib Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Dasatinib Tablet Registration in China
  • Chart Sales Value of Dasatinib Tablet over the World
  • Chart Sales Value of Dasatinib Tablet in China, 2016-2020
  • Chart Sales Value of Dasatinib Tablet in China by Regions, 2016-2020
  • Chart Sales Volume of Dasatinib Tablet in China, 2016-2020
  • Chart Sales Volume of Dasatinib Tablet in China by Regions, 2016-2020
  • Chart Market Share by Sales Value of Top Dasatinib Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of Yinish in China, 2016-2020
  • Chart Sales Value and Volume of SPRYCEL in China, 2016-2020
  • Chart Referential Prices of Yinish in China by Regions, 2020-2021
  • Chart Referential Prices of SPRYCEL in China by Regions, 2020-2021
  • Chart Forecast on Sales Value of Dasatinib in China, 2021-2025
  • Chart Forecast on Sales Volume of Dasatinib in China, 2021-2025